Cargando…

The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells

The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakisich, Juan Sebastian, Azad, Neelam, Kaushik, Vivek, Iyer, Anand K. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409035/
https://www.ncbi.nlm.nih.gov/pubmed/30918522
http://dx.doi.org/10.1155/2019/6254269
_version_ 1783401900012470272
author Yakisich, Juan Sebastian
Azad, Neelam
Kaushik, Vivek
Iyer, Anand K. V.
author_facet Yakisich, Juan Sebastian
Azad, Neelam
Kaushik, Vivek
Iyer, Anand K. V.
author_sort Yakisich, Juan Sebastian
collection PubMed
description The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated in vitro the anticancer activity of MET and BUF alone or in combination with 2-deoxy-D-glucose (2-DG) and WZB-117 (WZB), which are a glycolysis and a GLUT-1 inhibitor, respectively, in H460 human lung cancer cells growing under three different culture conditions with varying degrees of stemness: (1) routine culture conditions (RCCs), (2) floating lung tumorspheres (LTSs) that are enriched for stem-like cancer cells, and (3) adherent cells under prolonged periods (8-12 days) of serum starvation (PPSS). These cells are highly resistant to conventional anticancer drugs such as paclitaxel, hydroxyurea, and colchicine and display an increased level of stemness markers. As single agents, MET, BUF, 2-DG, and WZB-117 potently inhibited the viability of cells growing under RCCs. Both MET and BUF showed a strong synergistic effect when used in combination with 2-DG. A weak potentiation was observed when used with WZB-117. Under RCCs, H460 cells were more sensitive to MET and BUF and WZB-117 compared to nontumorigenic Beas-2B cells. While LTSs were less sensitive to each single drug, both MET and BUF in combination with 2-DG showed a strong synergistic effect and reduced cell viability to similar levels compared to the parental H460 cells. Adherent cells growing under PPSS were also less sensitive to each single drug, and MET and BUF showed a strong synergistic effect on cell viability in combination with 2-DG. Overall, our data demonstrates that the combination of BGs with either 2-DG or WZB-117 has “broad-spectrum” anticancer activities targeting cells growing under a variety of cell culture conditions with varying degrees of stemness. These properties may be useful to overcome the chemoresistance due to intratumoral heterogeneity found in lung cancer.
format Online
Article
Text
id pubmed-6409035
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64090352019-03-27 The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells Yakisich, Juan Sebastian Azad, Neelam Kaushik, Vivek Iyer, Anand K. V. Stem Cells Int Research Article The biguanides metformin (MET) and to a lesser extent buformin (BUF) have recently been shown to exert anticancer effects. In particular, MET targets cancer stem cells (CSCs) in a variety of cancer types but these compounds have not been extensively tested for combination therapy. In this study, we investigated in vitro the anticancer activity of MET and BUF alone or in combination with 2-deoxy-D-glucose (2-DG) and WZB-117 (WZB), which are a glycolysis and a GLUT-1 inhibitor, respectively, in H460 human lung cancer cells growing under three different culture conditions with varying degrees of stemness: (1) routine culture conditions (RCCs), (2) floating lung tumorspheres (LTSs) that are enriched for stem-like cancer cells, and (3) adherent cells under prolonged periods (8-12 days) of serum starvation (PPSS). These cells are highly resistant to conventional anticancer drugs such as paclitaxel, hydroxyurea, and colchicine and display an increased level of stemness markers. As single agents, MET, BUF, 2-DG, and WZB-117 potently inhibited the viability of cells growing under RCCs. Both MET and BUF showed a strong synergistic effect when used in combination with 2-DG. A weak potentiation was observed when used with WZB-117. Under RCCs, H460 cells were more sensitive to MET and BUF and WZB-117 compared to nontumorigenic Beas-2B cells. While LTSs were less sensitive to each single drug, both MET and BUF in combination with 2-DG showed a strong synergistic effect and reduced cell viability to similar levels compared to the parental H460 cells. Adherent cells growing under PPSS were also less sensitive to each single drug, and MET and BUF showed a strong synergistic effect on cell viability in combination with 2-DG. Overall, our data demonstrates that the combination of BGs with either 2-DG or WZB-117 has “broad-spectrum” anticancer activities targeting cells growing under a variety of cell culture conditions with varying degrees of stemness. These properties may be useful to overcome the chemoresistance due to intratumoral heterogeneity found in lung cancer. Hindawi 2019-02-21 /pmc/articles/PMC6409035/ /pubmed/30918522 http://dx.doi.org/10.1155/2019/6254269 Text en Copyright © 2019 Juan Sebastian Yakisich et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yakisich, Juan Sebastian
Azad, Neelam
Kaushik, Vivek
Iyer, Anand K. V.
The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_full The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_fullStr The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_full_unstemmed The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_short The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells
title_sort biguanides metformin and buformin in combination with 2-deoxy-glucose or wzb-117 inhibit the viability of highly resistant human lung cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409035/
https://www.ncbi.nlm.nih.gov/pubmed/30918522
http://dx.doi.org/10.1155/2019/6254269
work_keys_str_mv AT yakisichjuansebastian thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT azadneelam thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT kaushikvivek thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT iyeranandkv thebiguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT yakisichjuansebastian biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT azadneelam biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT kaushikvivek biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells
AT iyeranandkv biguanidesmetforminandbuforminincombinationwith2deoxyglucoseorwzb117inhibittheviabilityofhighlyresistanthumanlungcancercells